According to Zhitong Finance APP, the CRO concept has generally risen. As of the time of publication, Asymchem (06821) rose by 4.95% to HKD 59.4; Tigermed (03347) rose by 4.94% to HKD 38.25; WuXi AppTec (02359) rose by 3.88% to HKD 53.5; Kanglong Chemical (03759) rose by 2.73% to HKD 15.82; WuXi Biologics (02269) rose by 2.15% to HKD 17.12.
In terms of news, on November 2, the National Healthcare Security Administration introduced that the on-site negotiations for the adjustment of the national medical insurance drug catalog for 2024 have been successfully completed. The expanded new version of the medical insurance drug catalog is expected to be released to the public by the end of November, and will officially be implemented from January 1, 2025. Ping An Securities pointed out that the characteristics of the 2024 medical insurance negotiations are reflected in the low pass rate of the preliminary review and the limited number of negotiated varieties. In addition, this national negotiation focuses on &#34;accelerating the clinical application of innovative drugs,&#34; highlighting the innovative value of products.
CMB International stated that in the third quarter, companies like WuXi AppTec, Kanglong Chemical, and Asymchem, which mainly focus on overseas CDMO business, continued to benefit from the recovery of overseas R&amp;D demand, with new orders growing rapidly. The bank believes that the window period for the separate legislation of the biosafety bill within the year is very limited. Although the biosafety bill has passed in the U.S. House of Representatives, 49% of Democratic lawmakers did not vote in favor, including 36% against. It is expected that the &#34;Biosafety Bill&#34; will face greater resistance in the Democrat-controlled Senate. In a rate-cutting environment, global biopharmaceutical financing is expected to rebound, driving the recovery of CXO demand

603259

02359

300347

03347

002821

06821

The concept of CRO has generally risen, with Asymchem up 4.95%, Tigermed up 4.94%, and WuXi AppTec up 3.88%. The National Healthcare Security Administration announced that the negotiations for the adjustment of the 2024 medical insurance drug catalog have successfully concluded, with a focus on supporting innovative drugs. Ping An Securities pointed out that there are fewer varieties for negotiation, and the approval rate in the preliminary review is low. CMB International stated that companies like WuXi AppTec will benefit from the recovery of overseas R&D demand, and global biopharmaceutical financing is expected to rebound in a rate-cutting environment

Zhitong

WuXi AppTec

WUXI APPTEC

Tigermed

TIGERMED

Asymchem

Understanding the Market | The concept of CRO is generally rising, and Medicare negotiations support innovative drugs. In a rate-cutting environment, global biopharmaceutical financing will rebound